KROS Keros Therapeutics, Inc.

KROS financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1664710 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 5, 2026 Data checked: Nov 10, 2026
Showing 3 of 7 annual and 0 of 31 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$453.00M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Fiscal Year End
December (1231)
Phone
617-314-6297
EIN
811173868
Headquarters
LEXINGTON, MA, 02421
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
$40.42M
Net Income
$-61.73M
Total Assets
$307.37M
Total Equity
$279.10M
Total Debt
-
Free Cash Flow
$-48.27M
Ratios
Operating Margin
-181.3%
Net Margin
-152.7%
Return on Equity
-22.1%
Return on Assets
-20.1%
Current Ratio
18.14x
FCF / Assets
-15.7%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Keros Therapeutics, Inc. generated $243.86M of revenue in fiscal 2025, with net income of $87.01M and an operating cash inflow of $107.50M. At $243.86M, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Diluted earnings per share were $2.30, translating the period’s attributable earnings into the amount reported for each diluted share. At period end, total assets were $338.02M, framing the scale of the company’s operating and financing commitments. Asset turnover was 0.72x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

Operations produced $67.57M of income after the reported operating expense base, before the remaining non-operating and tax effects. Operating margin measured 27.7%, showing the portion of revenue preserved after the full set of operating costs. Net income came to $87.01M, completing the progression from revenue through gross and operating profitability to the final reported result. Measured against reported revenue, net income produced a 35.7% margin after operating costs and the remaining recognized items. EBITDA was $69.08M, adding a pre-interest, tax, depreciation, and amortization view of the company’s earnings capacity. The earnings statement records $91.90M of pretax income, the profit base against which the reported tax provision can be assessed. Pretax income represented 37.7% of revenue, placing earnings before tax in the context of the company’s operating scale. The reported income-tax provision was $4.88M, the amount recognized between pretax income and the final net-income result. Relative to pretax income, the tax provision measured 5.3%, quantifying the portion of pre-tax earnings paid in income tax. Net income equaled 28.7% of period-end equity, showing the earnings generated on shareholders’ book capital. The net-income-to-assets relationship measured 25.7%, showing earnings relative to the full balance sheet. The company moved from a $187.35M net loss in fiscal 2024 to net income of $87.01M.

Liquidity and Capital Structure

At period end, the $338.02M asset base was financed through $34.89M of liabilities and $303.13M of equity. Current assets were $315.43M against $20.41M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. Current assets covered current liabilities by 15.45x, leaving a positive buffer for near-term obligations. Cash and equivalents totaled $287.42M, identifying the most liquid reported component available within the broader current-asset balance. Book equity represented 89.7% of total assets, quantifying the balance-sheet share supported by shareholder capital. The liabilities-to-assets relationship was 10.3%, placing reported obligations against the full positive asset balance. Measured against total assets, cash and equivalents represented 85.0%, a balance-sheet composition measure rather than a liquidity forecast. Compared with $615.89M in fiscal 2024, the current asset base moved 45.1% and finished lower. Reported equity changed 47.0% from $571.55M in fiscal 2024, placing the current capital base lower year over year. The reported cash balance changed 48.7% from $559.93M in fiscal 2024, ending lower year over year.

Cash Flow and Earnings Quality

The company reported $107.50M of operating cash flow, a cash inflow that shows the cash generated by operations. The operating-cash-flow-to-net-income relationship was 1.24x, comparing cash generated by operations with the bottom-line earnings result. Capital spending was $1.55M, absorbing part of the cash generated from operations before free cash flow. Capital spending absorbed 1.4% of operating cash flow, quantifying the share of cash from operations directed to investment. After capital spending, free cash flow was $105.95M, leaving cash available for debt reduction, shareholder returns, or further investment. The free-cash-flow margin was 43.4%, measuring cash remaining after capital spending against revenue. The free-cash-flow-to-assets relationship was 31.3%, comparing post-investment cash with the balance-sheet asset base.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Keros Therapeutics, Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $243.86M $3.55M $151.00K
OPERATING EXPENSES
R&D Expense $129.64M $173.63M $135.26M
SG&A Expense $46.85M $40.75M $34.83M
Operating Income $67.57M $-210.83M $-169.94M
NON-OPERATING INCOME / EXPENSE
Interest Expense - $0 $0
Other Income/Expense $-539.00K $-954.00K $-206.00K
Pretax Income $91.90M $-187.05M $-152.99M
Income Tax $4.88M $300.00K $0
Net Income $87.01M $-187.35M $-152.99M
PER SHARE & SUPPLEMENTAL
Diluted EPS $2.30 $-5.00 $-5.20
Diluted Shares 37.86M 37.44M 29.45M
EBITDA $69.08M $-209.60M $-169.13M
Depreciation & Amortization $1.51M $1.23M $815.00K
Balance Sheet
ASSETS
Cash & Equivalents $287.42M $559.93M $331.15M
Accounts Receivable $3.57M $2.74M $143.00K
Other Current Assets $2.40M $1.45M $1.00M
Current Assets $315.43M $588.89M $347.29M
PP&E (Net) $4.30M $4.24M $4.13M
Other Noncurrent Assets $0 $2.06M $2.05M
Noncurrent Assets $22.59M $26.99M $22.73M
Total Assets $338.02M $615.89M $370.03M
LIABILITIES
Accounts Payable $1.97M $4.60M $5.45M
Other Current Liabilities $217.00K $416.00K $665.00K
Current Liabilities $20.41M $27.45M $24.37M
Noncurrent Liabilities $14.48M $16.88M $13.44M
Total Liabilities $34.89M $44.33M $37.81M
EQUITY
Common Stock $4.00K $4.00K $3.00K
Additional Paid-in Capital $1.17B $1.14B $713.64M
Retained Earnings $-481.77M $-568.78M $-381.43M
Total Equity $303.13M $571.55M $332.21M
Total Liabilities & Equity $338.02M $615.89M $370.03M
SUPPLEMENTAL
Shares Outstanding 19.54M 40.55M 31.84M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $107.51M $-160.87M $-124.51M
Capital Expenditures $1.55M $1.93M $2.46M
Cash from Investing $-1.55M $-1.93M $-2.46M
Cash from Financing $-378.47M $391.82M $178.96M
Free Cash Flow $105.95M $-162.80M $-126.97M
Beginning Cash (CFS) $561.38M $332.36M $280.38M
Net Change in Cash $-272.52M $229.02M $51.98M
Effect of FX on Cash - - -
Calculated Ending Cash $288.86M $561.38M $332.36M
Cash per BS $287.42M $559.93M $331.15M
Cash scope difference (CFS − BS) $1.45M $1.45M $1.21M
Cash per CFS $288.86M $561.38M $332.36M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is Keros Therapeutics, Inc.'s annual revenue?

Keros Therapeutics, Inc. reported $40.42M in revenue for trailing twelve months (ending September 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is Keros Therapeutics, Inc. profitable?

No. Keros Therapeutics, Inc. reported $-61.73M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does Keros Therapeutics, Inc. generate free cash flow?

No. Free cash flow was $-48.27M for trailing twelve months. Operating cash flow was $-47.85M.